Paul A. Vöhringer

Paul A. Vöhringer

Auto-generated profile, based on publicly available information

Paul A. Vöhringer

Departamento de Psiquiatría y Salud Mental Hospital Clínico Universidad de Chile Santiago Chile

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2013 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
RBRene Baudrand
Rene Baudrand
CCC. Campino
C. Campino
CCCristian Carvajal
Cristian Carvajal
OOOliviero Olivieri
Oliviero Olivieri
GGG. Guidi
G. Guidi
CFCarlos E. Fardella
Carlos E. Fardella


1 January 2013 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
PVPaul A. Vöhringer
Paul A. Vöhringer
SBSergio A. Barroilhet
Sergio A. Barroilhet
Andrea AmerioAndrea Amerio
Andrea Amerio
MRMaria Laura Reale
Maria Laura Reale
KAKatherine Alvear
Katherine Alvear
SGS. Nassir Ghaemi
S. Nassir Ghaemi
AIMS: Previous comparisons of cognitive decline among patients with bipolar disorder and schizophrenia have found somehow quite similar profiles of deficits, but results have varied between studies. Therefore an extensive and thoughtful systematic review of the matter is warranted. METHODS: Studies were found through systematic search (PubMed) following PRISMA guidelines. To be included, studies must have assessed the following cognitive functions: executive functions, memory, IQ, attention-concentration and perceptuomotor function. In order to make comparison between the two entities, studies should include bipolar disorder patients with operationally defined euthymia, schizophrenic patients in remission, and third group of healthy control patients. Comparisons were made after controlling for years of schooling and residual affective symptoms. RESULTS: We found that overall both SZ and BD patients present deficits on all neurocognitive measures compared to healthy controls (HC). In particular, SZ patients show more severe and pervasive cognitive deficits while BD patients present a milder and more confined impairment. In addition, evidence from the literature suggests that SZ and BD patients share a similar cognitive impairment profile with different degrees of deficits. Therefore, the difference between the two groups seems to be more quantitative (degree of deficit) rather than qualitative (profile), supporting a dimensional approach to the two clinical entities. Limitations of the present review includes the impossibility to control for effects of medication, varying time required for assessment across studies, illness diagnosis reliability and course severity CONCLUSIONS: Patients with bipolar disorder might exhibit a cognitive impairment that could be similar to schizophrenia in terms of their profile, although patients with schizophrenia may have more severe and widespread impairments.

1 September 2015 in Journal of Affective Disorders
Verified
Journal Article
Closed access
RERif S. El-Mallakh
Rif S. El-Mallakh
PVPaul A. Vöhringer
Paul A. Vöhringer
MOMichael M. Ostacher
Michael M. Ostacher
CBClaudia F. Baldassano
Claudia F. Baldassano
NHNiki S. Holtzman
Niki S. Holtzman
SGS. Nassir Ghaemi
S. Nassir Ghaemi

1 August 2014 in Journal of Affective Disorders
Verified
Journal Article
Closed access
Gabriele SaniGabriele Sani
Gabriele Sani
PVPaul A. Vöhringer
Paul A. Vöhringer
FNFlavia Napoletano
Flavia Napoletano
NHNiki S. Holtzman
Niki S. Holtzman
SDShannon Dalley
Shannon Dalley
AKAthanasios Koukopoulos
Athanasios Koukopoulos

19 June 2014 in Psychotherapy and Psychosomatics
Verified
Journal Article
Closed access
PDF file
GSGabriele Sani
Gabriele Sani
FNFlavia Napoletano
Flavia Napoletano
PVPaul A. Vöhringer
Paul A. Vöhringer
MSMatthew Sullivan
Matthew Sullivan
ASAlessio Simonetti
Alessio Simonetti
NGNassir Ghaemi
Nassir Ghaemi
Background: Mixed depression (MxD) is narrowly defined in the DSM-IV and somewhat broader in the DSM-5, although both exclude psychomotor agitation as a diagnostic criterion. This article proposes a clinical description for defining MxD, which emphasizes psychomotor excitation. Methods: Two hundred and nineteen consecutive outpatients were diagnosed with an MxD episode using criteria proposed by Koukopoulos et al. [Acta Psychiatr Scand 2007;115(suppl 433):50-57]; we here report their clinical features and antidepressant-related effects. Results: The most frequent MxD symptoms were: psychic agitation or inner tension (97%), absence of retardation (82%), dramatic description of suffering or weeping spells (53%), talkativeness (49%), and racing or crowded thoughts (48%). MxD was associated with antidepressants in 50.7% of patients, with similar frequency for tricyclic antidepressants (45%) versus selective serotonin reuptake inhibitors (38.5%). Positive predictors of antidepressant-associated MxD were bipolar disorder type II diagnosis, higher index depression severity, and higher age at index episode. Antipsychotic or no treatment was protective against antidepressant-associated MxD. Conclusions: MxD, defined as depression with excitatory symptoms, can be clinically identified, is common, occurs in both unipolar depression and bipolar disorder, and is frequently associated with antidepressant use. If replicated, this view of MxD could be considered a valid alternative to the DSM-5 criteria for depression with mixed features.